SEC Form 4 · accession 0001562180-16-002712
Sagent Pharmaceuticals, Inc. · SGNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Donald R Bullock
Officer — Executive V.P. Sales
Period of report
Jun 27, 2016
Accepted (ET)
Jun 28, 2016 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001369786
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 27, 2016 | A | 4,993 | $0.00 | A | 10,656 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option to BuyF1 | $15.02 | Jun 27, 2016 | A | 10,608 | A | — | Jun 27, 2026 | Common Stock | 10,608 | 10,608 | D |
Explanation of responses
- F1The option vests in four equal installments beginning on June 27, 2017.